Novartis AG is a global healthcare company that focuses on researching, developing, manufacturing, and marketing a wide range of healthcare products. It operates through two primary segments: Innovative Medicines, which contributes approximately 75% of revenue, and Sandoz, accounting for about 25%. The Innovative Medicines segment includes prescription medicines across various therapeutic areas such as ophthalmology, neuroscience, and immunology. The Sandoz segment specializes in generics and biosimilars, providing finished dosage forms and active pharmaceutical ingredients. The company's revenue is supported by a diverse product portfolio and strategic collaborations, but it faces challenges from patent expirations and competition in the generic market.
—
Novartis AG is a global healthcare company that focuses on researching, developing, manufacturing, and marketing a wide range of healthcare products. It operates through two primary segments: Innovative Medicines, which contributes approximately 75% of revenue, and Sandoz, accounting for about 25%. The Innovative Medicines segment includes prescription medicines across various therapeutic areas such as ophthalmology, neuroscience, and immunology. The Sandoz segment specializes in generics and biosimilars, providing finished dosage forms and active pharmaceutical ingredients. The company's revenue is supported by a diverse product portfolio and strategic collaborations, but it faces challenges from patent expirations and competition in the generic market.
—
Daily adjusted close
Novartis AG is a global healthcare company that focuses on researching, developing, manufacturing, and marketing a wide range of healthcare products. It operates through two primary segments: Innovative Medicines, which contributes approximately 75% of revenue, and Sandoz, accounting for about 25%. The Innovative Medicines segment includes prescription medicines across various therapeutic areas such as ophthalmology, neuroscience, and immunology. The Sandoz segment specializes in generics and biosimilars, providing finished dosage forms and active pharmaceutical ingredients. The company's revenue is supported by a diverse product portfolio and strategic collaborations, but it faces challenges from patent expirations and competition in the generic market.